Press Releases

Investors

Press Releases

 
Press Releases
  Date Title and Summary View
Dec 12, 2017
- Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2017 fourth quarter and year ended September 30, 2017. The company is hosting a conference call at 4:30 p.m...
Dec 6, 2017
— Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) presented new data from the company's Phase 2 clinical study in patients that received multiple doses of AR...
Dec 5, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, December 12, 2017, at 4:30 p.m. EST to discuss its financial results for the 2017 fiscal year ended September 30, 2017. Conference ...
Nov 14, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the company will make a presentation at the following upcoming event: 29th Annual Piper Jaffray Healthcare Conference - New York, November 28-29, 2017 November 28, 9:30 a...
Oct 23, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 17, 2017, eight new employees were awarded "inducement" grants of options under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The opti...
Oct 23, 2017
Data Presented in Late Breaking Poster Company Expects to File Clinical Trial Application in First Quarter 2018 to Begin First-in-Human Studies of ARO-AAT PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented data from stud...
Oct 10, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present preclinical data on ARO-AAT, a second generation investigational medicine for the treatment of alpha-1 liver disease that uses Arrowhead's TRiMTM technology, at The Liver Meeting® 2...
Oct 3, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the company will make a presentation at the following upcoming event: Chardan Gene Therapy Conference - New York, October 10, 2017 October 10, 10:45 a.m. EDT - Bruce Given, M.D., ...
Sep 27, 2017
- Results May Guide New Clinical Approaches, Science Translational Medicine Study Shows - PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced results from studies of ARC-520, a prior-generation RNAi therapeutic candidate against chronic ...
Sep 14, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), is hosting an investor & analyst R&D day in New York today to introduce its proprietary Targeted RNAi Molecule (TRiMTM) platform and review its pipeline of RNAi therapeutic candidates. Chris Anzalone, Ph.D...
Page:
1
... NextLast
= add release to Briefcase